Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy
Vascular Biology · 2019
DOI: 10.1530/vb-18-0001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vascular Biology, 2019. Verfasst von Jarkko P Hytönen und 8 weiteren Autor:innen. Beteiligte Einrichtung: A.I. Virtanen Institute of Molecular Medicine, University of Eastern Finland, Kuopio, Finland. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Prosthetic vascular grafts in humans characteristically lack confluent endothelialization regardless of the duration of implantation. Use of high-porosity grafts has been proposed as a way to induce endothelialization through transgraft capillarization, although early experiments failed to show increased healing in man.
Objectives
We hypothesized that transduction of tissues around the prosthetic conduit with vectors encoding VEGF receptor-2 (VEGFR2) ligands would augment transinterstitial capillarization and induce luminal endothelialization of high-porosity ePTFE grafts.
Methods
Fifty-two NZW rabbits received 87 ePTFE uni- or bilateral end-to-end interposition grafts in carotid arteries. Rabbits were randomized to local therapy with adenoviruses encoding AdVEGF-A165, AdVEGF-A109 or control AdLacZ and analyzed at 6 and 28 days after surgery by contrast-enhanced ultrasound and histology.
Results
AdVEGF-A165 and AdVEGF-A109 dramatically increased perfusion in perigraft tissues at 6 days (14.2 ± 3.6 or 16.7 ± 2.6-fold increases, P < 0.05 and P < 0.01). At 28 days, the effect was no longer significantly higher than baseline. At 6 days, no luminal endothelialization was observed in any of the groups. At 28 days, AdVEGF-A109- and AdVEGF-A165-treated animals showed enhanced ingrowth of transinterstitial capillaries (66.0 ± 13.7% and 77.4 ± 15.7% of graft thickness vs 44.7 ± 24.4% in controls, P < 0.05) and improved luminal endothelialization (11.2 ± 26.3% and 11.4 ± 22.2%, AdVEGF-A109 and AdVEGF-A165 vs 0% in controls, P < 0.05). No increased stenosis was observed in the treatment groups as compared to LacZ controls.
Conclusions
This study suggests that transient local overexpression of VEGFR2 ligands in the peri-implant tissues at the time of graft implantation is a novel strategy to increase endothelialization of high-porosity ePTFE vascular grafts and improve the patency of small-diameter vascular prostheses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- A.I. Virtanen Institute of Molecular Medicine, University of Eastern Finland, Kuopio, Finland.
- Molecular/Cancer Biology Laboratory, Biomedicum Helsinki, Helsinki, Finland.
- Department of Transplantation Surgery, Karolinska Hospital Huddinge, Karolinska Institute, Stockholm, Sweden.
- Heart Centre, North Karelia Central Hospital, Joensuu, Finland.
- Gene Therapy Unit, Kuopio University Hospital, Kuopio, Finland.
- Heart Center, Kuopio University Hospital, Kuopio, Finland.
Zitieren
APA
Hytönen, J. P., Leppänen, O., Taavitsainen, J., Korpisalo, P., Laidinen, S., Alitalo, K., Wadström, J., Rissanen, T. T., & Ylä-Herttuala, S. (2019). Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy. Vascular Biology. https://doi.org/10.1530/vb-18-0001
Vancouver
Hytönen JP, Leppänen O, Taavitsainen J, Korpisalo P, Laidinen S, Alitalo K, et al. Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy. Vascular Biology. 2019. doi:10.1530/vb-18-0001
BibTeX
@article{Hytnen2019,
author = {Hytönen, Jarkko P and Leppänen, Olli and Taavitsainen, Jouni and Korpisalo, Petra and Laidinen, Svetlana and Alitalo, Kari and Wadström, Jonas and Rissanen, Tuomas T and Ylä-Herttuala, Seppo},
title = {Improved endothelialization of small-diameter ePTFE vascular grafts through growth factor therapy},
journal = {Vascular Biology},
year = {2019},
doi = {10.1530/vb-18-0001}
}
EUVIMED